TY - JOUR
T1 - Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women
AU - Mello, Giorgio
AU - Parretti, Elena
AU - Fatini, Cinzia
AU - Riviello, Chiara
AU - Gensini, Francesca
AU - Marchionni, Mauro
AU - Scarselli, Gian Franco
AU - Gensini, Gian Franco
AU - Abbate, Rosanna
PY - 2005/1
Y1 - 2005/1
N2 - Data from literature report that angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism affects the recurrence of preeclampsia and that low-molecular-weight heparin (LMWH) prevents adverse outcomes in thrombophilic women. We investigated the effect of LMWH on the pregnancy outcome, on maternal blood pressure values, and on uteroplacental flow in ACE DD nonthrombophilic women with history of preeclampsia. Eighty nonthrombophilic ACE DD women were randomized in 2 groups: 41 treated with dalteparin 5000 IU/day and 39 untreated (control group). Women underwent 24-hour automated blood pressure monitoring in the preconceptional period and every 2 weeks from weeks 8 to 36 and transabdominal color flow/pulsed Doppler examination at weeks 16, 20, and 24. LMWH reduced the risk of clinical negative outcomes (74.1% reduction of preeclampsia and 77.5% reduction of fetal growth restriction) and the severity (88.3% reduction of early onset of preeclampsia and 86.4% reduction of early onset of fetal growth restriction). In treated women, the relative risk for preeclampsia was 0.26 (P=0.02), and the relative risk for fetal growth restriction was 0.14 (P
AB - Data from literature report that angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism affects the recurrence of preeclampsia and that low-molecular-weight heparin (LMWH) prevents adverse outcomes in thrombophilic women. We investigated the effect of LMWH on the pregnancy outcome, on maternal blood pressure values, and on uteroplacental flow in ACE DD nonthrombophilic women with history of preeclampsia. Eighty nonthrombophilic ACE DD women were randomized in 2 groups: 41 treated with dalteparin 5000 IU/day and 39 untreated (control group). Women underwent 24-hour automated blood pressure monitoring in the preconceptional period and every 2 weeks from weeks 8 to 36 and transabdominal color flow/pulsed Doppler examination at weeks 16, 20, and 24. LMWH reduced the risk of clinical negative outcomes (74.1% reduction of preeclampsia and 77.5% reduction of fetal growth restriction) and the severity (88.3% reduction of early onset of preeclampsia and 86.4% reduction of early onset of fetal growth restriction). In treated women, the relative risk for preeclampsia was 0.26 (P=0.02), and the relative risk for fetal growth restriction was 0.14 (P
KW - Angiotensin-converting enzyme
KW - Heparin
KW - Preeclampsia
UR - http://www.scopus.com/inward/record.url?scp=11244318197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11244318197&partnerID=8YFLogxK
U2 - 10.1161/01.HYP.0000149950.05182.a3
DO - 10.1161/01.HYP.0000149950.05182.a3
M3 - Article
C2 - 15557391
AN - SCOPUS:11244318197
VL - 45
SP - 86
EP - 91
JO - Hypertension
JF - Hypertension
SN - 0194-911X
IS - 1
ER -